Katsuya Hirose

Katsuya Hirose

Auto-generated profile, based on publicly available information

Katsuya Hirose

Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
ABAlexander T. F. Bell
Alexander T. F. Bell
PCPeter Chianchiano
Peter Chianchiano
KHKatsuya Hirose
Katsuya Hirose
DSDaniel Salas-Escabillas
Daniel Salas-Escabillas
DZDoreen M. Zucha
Doreen M. Zucha
LWLaura D. Wood
Laura D. Wood
In pancreatic ductal adenocarcinoma (PDAC), venous invasion (VI) is a critical step in metastasis and is associated with poor survival. However, little is known about the molecular features of VI. To investigate, we performed spatial transcriptomic analysis of 95 human PDAC tissue samples from eight treatment-naïve patients. Our analysis revealed that, compared with PDAC in stroma, PDAC with VI demonstrated up-regulation of genes associated with epithelial differentiation, classical subtype, and benign exocrine function. Conversely, PDAC with VI demonstrated down-regulation of genes associated with mesenchymal differentiation, basal-like subtype, and disease aggression. Additionally, we uncovered characteristics of VI morphology that correlated with these molecular features. VI–intraepithelial neoplasia–like foci had preserved venous architecture and had a classical, epithelial molecular phenotype, whereas VI-destructive foci had destroyed venous architecture and had a more basal-like, mesenchymal phenotype. We contextualized our findings using public RNA-seq data and observed that metastatic PDAC had greater similarity to PDAC in stroma than to PDAC with VI, whereas circulating tumor cells showed no preferential association. We confirmed our findings by spatial proteomic analysis of VI in an independent cohort of 19 treatment-naïve patients with PDAC. Overall, our work provides a reference atlas of spatial transcriptomics and proteomics of VI in PDAC and reveals unexpected increases in molecular features associated with better patient outcomes.

27 December 2023 in Pancreatology
Verified
Journal Article
Closed access
TYTakeichi Yoshida
Takeichi Yoshida
MDMohamad Dbouk
Mohamad Dbouk
KHKatsuya Hirose
Katsuya Hirose
EDElizabeth Abou Diwan
Elizabeth Abou Diwan
HSHelena Saba
Helena Saba
MGMichael Goggins
Michael Goggins

30 September 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Background: Cancer antigen 125 (CA125) is widely recognized as a useful biomarker for the surveillance of patients with ovarian and other cancers. Prior genome-wide association studies have identified variants that influence CA125 levels. We evaluated the utility of stratifying CA125 levels by such variants and evaluated diagnostic performance in control subjects and patients with pancreatic ductal adenocarcinoma (PDAC). Methods: We measured CA125 levels in 807 control subjects and 450 patients with PDAC and genotyped 10 variants involving four genes (GAL3ST2, MSLN, D2HGDH, and MUC16). We compared CA125 levels in controls by variant and generated variant-defined CA125 cutoffs and then classified cases and controls into functional groups based on their variant profile. We used this variant classification to evaluate the diagnostic performance of CA125 in patients with PDAC. Results: Six variants associated with CA125 levels were used to group controls into one of four groups. Mean CA125 levels in the highest variant group were approximately fourfold higher than in the lowest group. African Americans were more likely to have a variant group associated with low CA125 levels. After setting diagnostic cutoffs by variant group, the diagnostic sensitivity of CA125 for PDAC was 20.2% at 98% specificity (areas under the ROC curve, 0.702), not significantly different from a uniform CA125 diagnostic cutoff (areas under the ROC curve, 0.700). Conclusions: Gene variants can be used to generate personalized CA125 reference ranges. This approach did not significantly improve CA125’s diagnostic performance for pancreatic cancer, but it merits evaluation in other diagnostic settings, such as detecting ovarian cancer. Impact: Gene variants can be used to personalize CA125 levels.

1 December 2025
Verified
Other
Open access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Table S2: Clinicopathological features and CA125 levels in controls and patients with PDAC

1 December 2025
Verified
Other
Open access
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Figure S4: CA125 levels by variant group

1 December 2025
Verified
Other
Open access
PDF file
YHYuto Hozaka
Yuto Hozaka
AMAnne Macgregor-Das
Anne Macgregor-Das
MHMasataka Hayashi
Masataka Hayashi
TYTakeichi Yoshida
Takeichi Yoshida
ABAmanda Blackford
Amanda Blackford
MGMichael Goggins
Michael Goggins
Supplementary Table S6: Clinical features of PDAC cases with true positive vs false negative CA125 levels (variant-based classification)